Neurizon Therapeutics Completed Enrollment for ALS Trial
The company finished enrolling 250 participants for a phase II/III clinical trial evaluating the drug candidate NUZ-001.
Updated on Oct. 13, 2026 in Alzheimer’s
Live Poll
Do you trust that FDA regulatory pathways effectively prioritize patient safety while encouraging necessary medical innovation?
Neurizon Therapeutics has fully enrolled its 250-patient phase II/III trial for the ALS drug candidate NUZ-001. The FDA has indicated that this trial could potentially serve as a single registrational study for a future new drug application.
Why it matters
The company aims to secure regulatory approval for the drug as a treatment for ALS patients. The FDA has agreed to accept plasma neurofilament light chain measurements as supporting evidence for the study.
The phase II/III trial includes 250 patients across 78 U.S. clinical sites, a significant increase from the 12 patients in the prior proof-of-concept study. Additionally, an expanded access protocol for 200 patients is planned to run for 96 weeks.
The players
Neurizon Therapeutics
This pharmaceutical company, formerly known as Pharmaust Ltd., is focused on developing treatments for neurodegenerative conditions like ALS.
Sean M. Healey & AMG Center for ALS
Located at Mass General Brigham Hospital, this research center manages the platform trial for ALS therapies.
FDA
The U.S. Food and Drug Administration is the federal agency responsible for regulating drug approvals and clinical trial standards.
The details
The Healey ALS platform trial is being conducted at 78 sites across the United States under the management of the Sean M. Healey & AMG Center for ALS. While the FDA previously declined a request for fast track designation in January 2026, the current study is designed to support a future regulatory filing.
Timeline
October 2024: Pharmaust Ltd. changed its name to Neurizon Therapeutics.
January 2026: The FDA declined the fast track designation request for the drug.
Q1 2027: The expanded access protocol is expected to begin for patients.
Q2 2027: The company expects to report top-line trial results.
The Big Picture
This development follows the structure of the Healey ALS platform trial, which is designed to expedite the testing of experimental treatments for ALS. By utilizing a platform approach, researchers can more efficiently evaluate drug candidates compared to traditional, isolated clinical trial models.
The initiation of an expanded access program in 2027 may provide an additional treatment avenue for ALS patients who do not qualify for the primary trial. Patients should consult with their healthcare providers regarding these research opportunities and the status of the ongoing trial.
The takeaway
The transition of this trial into a potential registrational study highlights the evolving regulatory pathway for ALS treatments. Patients and their families should continue to monitor updates from the Sean M. Healey & AMG Center for ALS regarding enrollment and results.
What happens next
Neurizon Therapeutics expects to begin an expanded access program for 200 patients in the first quarter of 2027. Top-line results from the phase II/III trial are anticipated in the second quarter of 2027, followed by a potential NDA submission 18 months after that readout.
Further reading
For more information on current clinical research, visit United States Alzheimer’s.
Source note: This article includes information reported by Bio World.
Live Poll
Do you trust that FDA regulatory pathways effectively prioritize patient safety while encouraging necessary medical innovation?
